Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

Completed · Phase 2 · Has a placebo group

Conditions studied: Lupus Erythematosus, Systemic

In brief

The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.

Key facts

Study ID
NCT00071487
Run by
Human Genome Sciences Inc.
People needed
449
Starts
2003-10-01
Expected to finish
2006-06-01
Last updated by the study team
2013-08-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.